Abstract: Compounds having formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are selected from the group consisting of hydrogen, hydroxy and methoxy. At most one of R.sup.1, R.sup.2 and R.sup.3 and at most one of R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is selected from the group consisting of hydroxy and methoxy. M is selected from the group consisting of hydrogen and pharmaceutically acceptable inorganic or organic cations or tautomeric forms thereof. The compounds have immunomodulating activity.

Abstract: The invention relates to emulsions intended for parenteral administration and contaning a hydrophobic phase emulsified in a an aqueous phase. In accordance with the invention, a substantial part of the hydrophobic phase contains one or more alkyl esters of pharmacologically acceptable fatty acids, and particularly their ethyl esters. The emulsions can be used for parenteral nutrient supply and as vehicles for pharmacologically active substances or agents and may also be used for both purposes in combination.

Abstract: The invention concerns compounds having the formula I ##STR1## wherein Ar is a phenyl or benzyl group which is optionally substituted with hydroxy or alkoxy;R.sup.1 is hydrogen, lower alkyl, lower alkoxy, hydroxy;R.sup.2 is hydrogen, lower alkyl;R.sup.3 is NR.sup.4 R.sup.5, whereinR.sup.4 and R.sup.5 which can be the same or different, are lower alkyl, or wherein R.sup.4 and R.sup.5, when taken together, form a ring with the nitrogen atom, whereby said ring optionally is substituted with lower alkyl;n is 0 or 1;m is 2 or 3 andtheir salts with physiologically acceptable acids and when the compounds can be in form of optical isomers, the racemic mixture and the individual isomers, for the treatment of disorders of the urinary bladder.

Abstract: The invention concerns intermediates having the formula ##STR1## wherein R is 2-propylpentyl optionally with one, two or three internal unsaturated bonds, or 2-substituted-2-propylpentyl optionally with one or two internal unsaturated bonds wherein the 2-substituent is a leaving group.

Abstract: Therapeutically active organic compound exhibiting at least one group comprising a structure --S'--S"--R, wherein the group --S"--R is defined by R being an organic group comprised in a physiologically acceptable compound H--S"--R obtainable by the splitting of the disulfide bridge --S'--S"-- in said structure, in which compound H--S"--R the sulfur atom S" is bound to a carbon atom in a heterocyclic aromatic ring in R having a configuration being such that the compound H--S"--R, while maintaining physiological acceptability, is stabilized, by tautomerism or resonance involving the sulfur atom S" bound to R, so as to be mainly excluded from reaction involving thiol disulfide exchange; S' being bound to an aliphatic carbon atom; and said compound, in addition to the group or groups comprising the structure --S'--S"--R, consisting of a residue of a therapeutically active organic base compound of non-polypeptide structure bound to S'.

Abstract: Therapeutically active organic compound exhibiting at least one radical comprising a structure --S'--S"--R, where S"--R is defined by R being an organic group comprised in a physiologically acceptable compound H--S"--R obtainable by the splitting of the disulfide bridge --S'--S"-- in said structure, in which compound H--S"--R the sulfur atom S" is bound to a carbon atom in a heterocyclic aromatic ring in R having a configuration being such that the compound H--S"--R, while maintaining physiological acceptability, is stabilized, by tautomerism or resonance involving the sulfur atom S" bound to R, so as to be mainly excluded from further reaction involving thiol disulfide exchange; S' being bound to an aliphatic carbon atom; and said compound, in addition to the group or groups comprising the structure --S'--S"--R, also consisting of a residue of a therapeutically active organic base compound of polypeptide structure bound to S', for therapeutical use in mammals, including humans.

Abstract: A separation material of crosslinked agarose in which the agarose is crosslinked using at least one bi- or polyfunctional crosslinking agent, which gives a chain of 6 to 12 atoms between two binding points, on one hand and using at least one bifunctional crosslinking agent, which gives a chain of 2 to 5 atoms between two binding points on the other.The separation material is prepared by crosslinking agarose in two steps with (a) a bi- or polyfunctional crosslinking agent, which gives a chain of 6 to 12 atoms between two binding points and (b) a bifunctional crosslinking agent, which gives a chain of 2 to 5 atoms between two binding points, preferably in the order mentioned.

Abstract: There is described a method for splitting at least one disulphide bond --S--S--, where each of the sulphur atoms is directly bound covalently to its respective aliphatic carbon atom in an organic substance which contains at least one such disulphide bond, in which each bond --S--S-- which is split is converted substantially to two reactive groups of the formulae --S--S--R.sub.1 and R.sub.2 --S--S--, where R.sub.1 and R.sub.2 are equal or different and each is an organic residue. Splitting of the bond is effected by reacting said organic substance with a mixture of a compound R.sub.3 --S--S--R.sub.4 and a compound capable of existing in the tautomeric forms R.sub.5 --S--H and HR.sub.5 .dbd.S or corresponding resonance-stabilized anion forms, in which compounds the residues R.sub.3, R.sub.4 and R.sub.5 (i) are organic residues of which all are different, two are equal or all are equal, and (ii) are defined in (a) that each of the aforesaid sulphur atoms in the compounds R.sub.3 --S--S--R.sub. 4 and R.sub.

Abstract: The present invention relates to a method and material for cleansing fluid discharging skin surfaces, wounds and mucous membranes, which method and material includes the use of a material comprising certain water-insoluble hydrophilic polymers.

Abstract: The present invention relates to a method and material for cleansing fluid discharging skin surfaces, wounds and mucous membranes, which method and material includes the use of a material comprising certain water-insoluble hydrophilic polymers.

Abstract: A sterile aqueous solution containing 0.

Abstract: A diagnostic agent for intravascular administration into blood vessels composed of radioactively labelled particles suspended in a physiologically acceptable aqueous liquid, said particles having a size so selected that they clog fine blood vessels having a diameter within the range 5 - 300 .mu.m, said particles consisting of a three-dimensional, water-insoluble, hydrophilic, swellable, cross-linked network of polysaccharide substances, and the method of using this diagnostic agent.

Abstract: The present invention relates to an agent for intravascular administration, said agent consisting of a suspension of minute polysaccharide particles having a size such that subsequent to being administered intravascularly, they block the finer blood vessels of the body and a diagnostic agent.

Abstract: An X-ray contrast preparation comprising a) a finely divided water-insoluble inorganic X-ray contrast producing substance and b) minute particles of a hydrophilic polymer containing amino groups, which polymer is insoluble in water at body temperature and which consists of a water-insoluble, but water-swellable three-dimensional network held together by bonds of a covalent nature, said polymer containing a certain amount of amino groups and the average particle size of the polymer particles lying within a certain range. The preparation is intended for the X-ray examination of body cavities having outer discharge orifices. It adheres very effectively to the walls of the body cavities.

Abstract: A method for the preparation of 2-[4-(4-hydroxy-3-carboxyphenylazo)-benzenesulfonamido]-pyridine by reacting 4-diazobenzenesulfonic acid with an ester of salicyclic acid having the formula ##STR1## in the presence of an alkali metal hydroxide to form a first reaction product having the formula ##STR2## reacting said first reaction product with an acylating agent to form a second reaction product having the formula ##STR3## treating said second reaction product with thionyl chloride in the presence of a tertiary formamide to form a chlorinated compound having the formula ##STR4## reacting said chlorinated compound with 2-amino-pyridine under water-free conditions in the presence of an acid binding agent, to form a third reaction product having the formula ##STR5## treating said third reaction product with alkali metal hydroxide in the presence of water to hydrolyze off the R and R.sub.1 groups, and recovering 2-[4-(4-hydroxy-3-carboxyphenylazo)-benzenesulfonamido]-pyridin e.

Abstract: The neck opening of a filled plastic bottle is sealed by a sealing unit ultrasonically welded to the top of the neck. The sealing unit can be a one-piece member having an upwardly projecting hollow portion arranged to be broken off to provide an opening for dispensing the contents of the bottle. Alternatively, the sealing unit can be composed of an inner cap, an outer cap and a sealing disc interposed between the caps, this unit being arranged to be pierced by a cannula for withdrawing the contents of the bottle.

Abstract: A foam forming composition consisting of a mixture of a hydrocarbon and/or a lipophilic hydrocarbon derivative, water, a liquified propellant and a surface active agent or mixture of such agents in such proportions as to obtain a mesomorphic phase, the surface active agent or agents being soluble in the water and the hydrocarbon and/or the lipophilic hydrocarbon derivative.

Abstract: A method of binding, in the presence of a liquid, at least one immunoglobulin or its free Fc-fragment, the immunoglobulin being in free form or with its Fab-part bound to an antigen to which is optionally in turn bound one or more groups or substances, to a polymer insoluble in said liquid with the assistance of a substance attached to the polymer. The substance used is at least one polypeptide from microorganisms to which polypeptide the Fc-part of the immunoglobulin or its free Fc-fragment can bind itself.

Abstract: A pharmaceutical product containing amino groups, which product:A. is comprised of residues of one or more diamines of the general formulaH.sub.2 N.CH.sub.2. phenylene.CH.sub.2.NH.sub.2 (I)which residues are interconnected by bridges between the residues to form a three-dimensional network, the bridges being bound to nitrogen atoms in the residues (I) and comprise straight or branched aliphatic, saturated hydrocarbon chains substituted with one or more hydroxyl groups and containing 3-30 carbon atoms, preferably 3-16 carbon atoms and which are optionally broken by one or more oxygen atoms, the amino groups being present in a free form or in the form of (the cation portion of) a non-toxic salt, andB. is insoluble in water or other solvents, but capable of swelling in water to gel form, 1 g of the dry product in the form of an HCl salt in the presence of water swelling to at least 5 ml and to at most 50 ml, preferably to at least 5 ml and to at most 25 ml, andC.

Abstract: A composition in the form of a solid shaped body adapted for insertion in the cavity of the eye and containing a substance having a topical effect on the eye, which composition comprises a mixture of 5 - 90 % of at least one lipophilic substance having a melting point of 37.degree. - 75.degree.C, 0 - 40 % of at least one water-soluble or water-swellable polymer in solid, finely-divided form, 0.05 - 30 % of at least one drug having a topical effect on the eye and 0.2 - 20 % of at least one water-insoluble lipophilic polymer having a softening temperature exceeding 70.degree.C and a melting point exceeding 85.degree.C and which is soluble in the lipophilic substance or substances in molten form to serve as stabilizer for the mixture, the percentages relating to percent by weight calculated on the total weight of the mixture.